IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3491
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$733M
Carl W. Hull
Maravai LifeSciences Holdings, Inc. provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. | 40 | 36 | 46 | 41 | - | - | -78.8% | -40.1% | 23.3% | -145.8% | -154.6% | -40.0% | 0.0% | 68.0x | $733M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) receives a "Reduce" rating with a composite score of 40.4/100. It ranks #3491 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for MRVI.
View All RatingsROIC -65.8% vs WACC 6.6% (spread -72.5%)
GM 23% vs sector 44%, OM -146% vs sector 3%
Capital turnover 0.85x, R&D intensity 10.0%
Rev growth -40%, 5yr history
Interest coverage -6.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) as a Reduce with a composite score of 40.4/100 at a current price of $3.13. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
MARAVAI LIFESCIENCES HOLDINGS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 40.4/100 places it at rank #3491 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
MARAVAI LIFESCIENCES HOLDINGS, INC. represents a reduce based on multi-factor quantitative performance.
MARAVAI LIFESCIENCES HOLDINGS, INC. receives a Reduce rating from our analysis, with a composite score of 40.4/100 and 2 out of 5 stars, ranking #3491 out of 7,333 stocks. MRVI's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
MRVI's quality score of 36/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -78.8% (sector avg: -1.9%), gross margins of 23.3% (sector avg: 44.1%), net margins of -154.6% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 46/100, MRVI appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 1.04x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
MARAVAI LIFESCIENCES HOLDINGS, INC.'s investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -40.0% vs. a sector average of 6.7% and a return on assets of -40.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
MRVI is currently showing below-average momentum at 41/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -40.0% year-over-year, while a beta of 1.36 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
MRVI's stability score of 40/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.36 and a debt-to-equity ratio of 68.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
MARAVAI LIFESCIENCES HOLDINGS, INC.'s short interest score of 35/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.36), elevated leverage (D/E: 68.00x), small-cap liquidity risk. At $733M (small-cap), MRVI carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
MARAVAI LIFESCIENCES HOLDINGS, INC. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3491 of 7,333 overall (52nd percentile). Key comparisons include ROE of -78.8% trailing the -1.9% sector median and operating margins of -145.8% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MRVI currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (35) would have the largest impact on the composite score.
ROE 4046% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 47% BELOW SECTOR MEDIAN
Op. Margin 5909% BELOW SECTOR MEDIAN
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who purchased shares between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its revenue recognition, internal controls, and goodwill, leading to an overstatement of its financial prospects. Shareholders with losses during this period have until May 5, 2025, to seek appointment as lead plaintiff.
Kirby McInerney LLP is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a federal securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai failed to disclose inadequate internal controls over revenue recognition and an overstatement of goodwill, leading to a significant stock price decline on February 25, 2025, after the company announced delays in its earnings release and annual report due to an identified error in revenue recognition and a potential non-cash impairment charge. Investors who purchased Maravai securities during the Class Period (August 7, 2024, through February 24, 2025) are encouraged to contact the law firm to discuss their rights.
Rosen Law Firm is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its financial reporting and goodwill. Investors who purchased Maravai securities between August 7, 2024, and February 24, 2025, are encouraged to secure counsel.
Levi & Korsinsky has filed a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of shareholders who suffered losses due to alleged securities fraud between August 7, 2024, and February 24, 2025. The lawsuit claims that Maravai made false statements and concealed issues regarding its internal controls over financial reporting, leading to inaccurate revenue recognition and an overstatement of goodwill. Shareholders affected during this period are encouraged to seek information on potential recovery.
Pomerantz LLP has filed a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who suffered losses. The lawsuit stems from Maravai's announcement of postponing its fiscal 2024 earnings release and delaying its annual report due to an identified error in revenue recognition and a material weakness in internal controls, which caused the stock price to drop significantly. Investors have until May 5, 2025, to apply to be appointed as Lead Plaintiff.
Above 50MA
37.18%
Net New Highs
+51081